Adoptive CAR T Cell Therapy Targeting GD2-Positive Cancers

Cytotoxic lymphocytes expressing chimeric antigen receptor (CAR) are emerging as promising therapeutic options for patients with hematological malignancies and solid tumors. We developed a new CAR against the disialoganglioside GD2, a surface molecule expressed in different central nervous system neoplasms, such as glioblastoma. The anti-GD2 single-chain variable fragment (scFv) derived from a murine antibody of IgM class was linked, via a human...